Stay updated on Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.0%
    Check dated 2024-06-13T22:40:43.000Z thumbnail image
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to a clinical trial for HER2 positive breast cancer treatment involving tucatinib, capecitabine, and trastuzumab.
    Difference
    0.0%
    Check dated 2024-06-06T14:41:08.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has updated the 'Participation Criteria' section to provide detailed information about the eligibility criteria for participants, including specific health conditions and prior treatments required for inclusion in the study. Previously, this section had no information provided.
    Difference
    29%
    Check dated 2024-05-22T21:11:21.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2024-04-30T22:25:22.000Z thumbnail image

Stay in the know with updates to Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucatinib Combo in Advanced HER2+ Breast Cancer Clinical Trial page.